Patent Update: Pulmonary-Allergy, Dermatological, Gastrointestinal & Arthritis: Platelet-activating factor receptor antagonists

References

• WHITTAICER M: PAF receptor antagonists: Recent advances. Curr. Opin. Thera. Patents (1992) 2: 583–623.
   Google Scholar
• A review of the PAF antagonist patent literature published from January 1991 through to March 1992 that includes a new classification of PAF antagonists.
   Google Scholar
• WHITTAKER M. Patent News: Platelet-activating factor receptor antagonists. Curr. Opin. Thera. Patents (1993) 3: 1569–1573.
   Google Scholar
• ZIMMERMAN GA, PRESCOTT SM, MCINTYRE TM: Platelet-activating factor: A fluid-phase and cell-associated me-diator of inflammation. In: Inflammation: Basic Principles and Clinical Correlates (Second Edition) Gallin JI, Goldstein IM, Snyderman R (Eds.) Raven Press, New York (1992) pp 149–176.
   Google Scholar
• Excellent review on PAF biology that also includes a discussion of oxidised phospholipids that can act as PAF receptor agonists.
   Google Scholar
• VENABLE ME, ZIMMERMAN GA, MCINTYRE TM, PRESCOTTSM: Platelet-activating factor: A phospholipid autacoid with diverse actions. J. Lipid Res. (1993) 34: 691–702.
   PubMed Web of Science ®Google Scholar
• MCMANUS LM, WOODARD DS, DEAVERS SI, PINCKARD RN: PAF molecular heterogeneity: Pathobiological im-plications. Lab. Invest. (1993) 69: 639–650.
   PubMed Web of Science ®Google Scholar
• SHULKA SD: Platelet-activating factor receptor and sig-nal transduction mechanisms. FASEB J. (1992) 6: 2296–2301.
   PubMedGoogle Scholar
• SHIMIZU T, HONDA Z, NAICAMURA M, BITO H, IZUMI T: Platelet-activating factor receptor and signal transduc-tion. Biochem. Pbarmacol. (1992) 44: 1001–1008.
   PubMed Web of Science ®Google Scholar
• SHIMIZU T: Molecular cloning of platelet-activating fac-tor receptors. In: Platelet-activating factor receptor-signal mechanisms and molecular biology, Shulka SD (Ed.), CRC Press, Boca Raton (1993) pp 29–40.
   Google Scholar
• CHAO W, OLSON MS: Platelet-activating factor: Receptors and signal transduction. Biochem. J. (1993) 292: 617–629.
   PubMed Web of Science ®Google Scholar
• A thorough review of the molecular pharmacology of the PAF receptor.
   Google Scholar
• BAZAN HEP, TAO Y, HURST JS: Platelet-activating factor antagonists and ocular inflammation. J. Ocular Pharma-col. (1994) 10: 319–327.
   PubMedGoogle Scholar
• DESQUAND S: Effects of PAF antagonists in experimen-tal models: Possible therapeutical implications. Thera-pie (1993) 48: 585–597.
   Google Scholar
• HANDLEY DA, CERASOLI F Jr.: PAF antagonists as asthma therapeutics. In: Drugs and the Lung, Page CP, Metzger Nli7J (Eds) Raven Press: New York (1994) pp 467–505.
   Google Scholar
• TRAVIS SPL, JEWELL DP: The role of platelet-activating factor in the pathogenesis of gastrointestinal disease. Prostaglandins Leukot. Essent. Fatty Acids (1994) 50: 105–113.
   PubMedGoogle Scholar
• DEJOY SQ, ORONSKY AL, WICK MM, KERWAR SS: Preclini-cal studies with platelet-activating factor antagonists in models of septic shock. Int. J. Antimicrobial Agents (1993) 3: 175–186.
   PubMedGoogle Scholar
• KOLTAI M, HOSFORD D, BRAQUET P: PAF-induced am-plification of mediator release in septic shock Preven-tion or downregulation by PAF antagonists. J. Lipid Mediators (1993) 6: 183–198.
   PubMedGoogle Scholar
• SÁNCHEZ CRESPO M: Potential of PAF receptor antago-nists in the treatment of septic shock. Drug News Perspec-tives (1993) 6: 78–87.
   Google Scholar
• Review includes discussion of the interaction of PAF with other inflammatory mediators in septic shock.
   Google Scholar
• EVANGELOU AM: Platelet-activating factor (PAF): Impli-cations for coronary heart and vascular diseases. Pro-staglandins Leukot. Essen:. Fatty Acids (1994) 50: 1–28.
   PubMed Web of Science ®Google Scholar
• BENFIELD TL, LUNDGREN JD: PAF receptor antagonists In the treatment of asthma. Exp. Opin. Invest. Drugs (1994) 3: 733–742.
   Google Scholar
• HWANG S-B: Platelet-activating factor: Receptors and receptor antagonists. In: Immunopharrnacology of Lipid Mediators. Cuningham F (Ed.), Academic Press, London (1994) pp 297–360.
   Google Scholar
• KOLTAI M, GUINOT P, HOSFORD D, BRAQUET PG: Plate-let-activating factor antagonists: Scientific background and possible clinical applications. Adv. Pharmacol. (1994) 28: 81–167.
   PubMedGoogle Scholar
• TAKATANI M, TSUSHIMA S: Structure activity relationships in CV-3988 and CV-6209 PAF antagonist series. In: CRC Handbook of PAF and PAF antagonists, CRC Press (1991) pp 97–118.
   Google Scholar
• SAR and pharmacology of these important early PAF antagonists is presented.
   Google Scholar
• VENUTI MC: Platelet-activating factor receptors. In: Comprehensive Medicinal Chemistry (vol. 3), Hansch C, Sammes PG, Taylor JB (Eds.) Pergamon (1990) pp 715–761. A thorough review that includes a comprehensive survey of PAF agonist SAL.
   Google Scholar
• VILLA L, PALLAVICINI M, VILLA AM, VALOTI E, FERRI V, MADERNA V: Chiral PAF agonists: Synthesis, theoretical analysis of their stereoelectronic properties and struc-ture activity relationships. ll Farmaco (1993) 48: 573–613.
   PubMedGoogle Scholar
• VILLA L, PALLAVICINI M, VILLA AM, VALOTI E, FERRI V, BERTI F: Agonist activity and charge driven interaction potentiality of PAF derivatives. II Farmaco (1993) 48: 1379–1399.
   PubMedGoogle Scholar
• SMILEY PL, STREMLER ICE, PRESCOTT SM, ZIMMERMAN GA, MCINTYRE TM: Oxidatively fragmented phosphatidyl-cholines activate human neutrophils through the re-ceptor for platelet-activating factor./ Biol. Chem. (1991) 266: 11104–11110.
   PubMedGoogle Scholar
• PATEL ICD, ZIMMERMAN GA, PRESCOTT SM, MCINTYRETM: Novel leukocyte agonists are released by endothe-lial cells exposed to peroxide. J. Biol. Chem. (1992) 267: 15168–15175.
   PubMedGoogle Scholar
• MCINTYRE TM, PATEL KID, SMILEY PL, STAFFORINI D, PRESCOTT SM, ZIMMERMAN GA: Oxidised phospholipids with PAF-like bioactivity. J. Lipid Mediators Cell Signalling (1994) 10: 37–39.
   Google Scholar
• Brief summary of the field of oxidised phospholipids.
   Google Scholar
• TOKUMURA A, TANAKA T, YOTSUMOTO T, TSUKATANI H: Formation of PAP-like compounds by peroxidation of phospholipids from bovine brain. J. Lipid Mediators (1992) 5: 127–130.
   PubMedGoogle Scholar
• TANAKA T, MINAMINO H, UNEZAKI S, TSUKATANI H, TOKUMURA A: Formation of platelet-activating factor-like phospholipids by Fe2./ascorbate/EDTA-induced lipid peroxidation. Biochim. Biophys. Acta (1993) 1166: 264–274.
   PubMedGoogle Scholar
• TANAKA T, TIMOR' M, TSUKATANI H, TOKUMURA A: Platelet-aggregating effects of platelet-activating factor-like phospholipids formed by oxidation of phospha-tidylcholines containing an sn-2-polyunsaturated fatty acyl group. Biochim. Biophys. Acta (1994) 1210: 202–208.
   PubMedGoogle Scholar
• TOKUMURA A, TANAKA T, TSUKATANI H: Charac-terization of PAF-like phospholipids formed by lipid peroxidation. J. Lipid Mediators Cell Signalling (1994) 10: 179–181.
   Google Scholar
• O'FLAHERTY JT, TESSNER T, GREENE D, REDMAN JR,WYICLE RL: Comparison of 1-0-alkyl-, 1-0-alk-1'-enyl-, and 1-0-acy1-2-acetyl-sn-glycero-3-phosphoethano-lamines and -3-phosphocholines as agonists of the platelet-activating factor family. Biochim. Biophys. Acta (1994) 1210: 209–216.
   PubMedGoogle Scholar
• CHILTON FH, FONTEH AN, IBERICO M, BASS DA, TRIG-GIANT M: Natural occurrence, synthesis, catabolism and biological activity of 1-acy1-2-acetyl-sn-glycero-3-phos-phocholine. J. Lipid Mediators Cell Signalling (1994) 10: 47–51.
   Google Scholar
• STREMLER RE, STAFFORINI DM, PRESCOTT SM, ZIMMERMAN GA, MCINTYRE TM: An oxidised derivative of phos-phatidylcholine is a substrate for the platelet-activating factor acetylhydrolase from human plasma. J. Biol. Chem. (1989) 264: 5331–5334.
   Google Scholar
• STREMLER KE, STAFFORINI DM, PRESCOTT SM, MCINTYRE TM: Human plasma platelet-activating factor acetylhy-drolase. J . Biol. Chem, (1991) 266: 11095–11103.
   PubMed Web of Science ®Google Scholar
• STAFFORINI DM, ROLLINS EN, PRESCOTT SM, MCINTYRE TM: The platelet-activating factor acetylhydrolase from human erythrocytes. J. Biol. Chem. (1993) 268: 3857–3865.
   PubMedGoogle Scholar
• AMBROSIO G, ORIENTE A, NAPOLI C, PALUMBO G, CHIARIELLO P, MARONE G, CONDORELLI M, CHIARELLO M, TRIG GIANI M: Oxygen radicals inhibit human plasma acetylhydrolase, the enzyme that catabolizes platelet-activating factor. J. Clin. Invest, (1994) 93: 2408–2416.
   PubMed Web of Science ®Google Scholar
• RUBWURM S, KRAUSE S, FINKELBERG L, ROHLING K, SCHAUER U, LOSCHE W: Generation of reactive oxygen species and activity of platelet-activating factor acetyl-hydrolase in human monocyte-derived macrophages. Thromb. Res. (1994) 74: 505–514.
   PubMedGoogle Scholar
• NAGAOKA J, HARADA K, KIMURA A, KOBAYASHI S, MURAKAMI M, YOSHIMURA T, YAMADA K, ASANO O, KATAYAMA K, YAMATSU I: Inhibitory effects of the novel platelet-activating factor receptor antagonist, 1-ethy1-2-[N-(2-methoxy) benzoyl-N-K2R)-2-methoxy-3-(4-oc-tadecylcarbamoyloxy)piperidino-carbonyloxypropyl-oxyl-carbonylaminomethylpyridiniumchloride, in sev-eral experimentally induced shock models. Arzneimit-telforschung/Drug Res. (1991) 41(II): 719.
   Google Scholar
• First detailed report on the pharmacology of the Eisai PAF antagonist E-5880. Comparative data are given for CV-3988 and CV–6209.
   Google Scholar
• SUZUKI H, ASANO 0, TADANO K, HORIE T: Radioimmu-noas say for the novel platelet-activating factor receptor antagonist E-5880. j Pharmaceut. Sci. (1994) 83: 657–661.
   PubMedGoogle Scholar
• Oh MC, KAMBAYASHI J, KAWASAKI T, UEMURA Y, SHI-NOZAKI K, SHIBA E, SAKON M, YUKAWA M, MORI T: Potential etiologic role of PAP in two major septic complications: Disseminated intravascular coagulation and multiple organ failure. Thromb. Res. (1994) 73: 227–238.
   PubMedGoogle Scholar
• Scrip (1992) 1728: 12.
   Google Scholar
• HOULIHAN WJ: Structure activity relationships in cyclic analogs of PAP with PAP antagonist properties. In: CRC Handbook of PAF and PAF antagonists, CRC Press (1991) pp 157–170.
   Google Scholar
• VITI G, NANNICINI R, RICCI R, PESTELL1NI V, ABELLI L,FURIO M: New antagonists of platelet-activating factor containing 2-oxazolidinone or 2-morpholinone. Eur. J. Med. Chem. (1994) 29: 401–406.
   Web of Science ®Google Scholar
• WISSNER A, CARROLL ML, GREEN KE, KEWAR SS, PICKETT WC, SCHAUB RE, TORLEY LW, WRENN S, KOHLER CA: Analogues of platelet activating factor. 6. Mono- and bis-aryl phosphate antagonists of platelet-activating factor. J. Med. Chem. (1992) 35: 1650–1662.
   Google Scholar
• Detailed report on the SAR of the American Cyanamid development compound CL 184,005 and its analogues.
   Google Scholar
• WISSNER A, CARROLL ML, JOHNSON BD, KEWAR SS, PICKETT WC, SCHAUB RE, TORLEY LW, TROVA MP, KO-HLER CA: Analogues of platelet-activating factor. 7. Bis-aryl anaide and his aryl urea receptor antagonists of PAF. J. Med. Chem. (1992) 35: 4779–4789.
   Google Scholar
• TROVA MP, WISSNER A, CARROLL ML, KEWAR SS, PICKETTWC, SCHAUB RE, TORLEY LW, KOHLER CA: Analogues of platelet-activating factor. 8. Antagonists of PAP contain-ing an aromatic ring linked to a pyridinium ring. J. Med. Chem. (1993) 35: 580–590.
   Google Scholar
• KOHLER C, CARROLL M, TARRANT E, TORLEY L, WISSNER A: Effect of a series of 1-alkyl ether lipids on inhibition of phospholipase A2 activity and PAP responses. Inflam-mation (1993) 17: 245–261.
   PubMedGoogle Scholar
• CARCELLER E, MERIOS M, GIRAL M, BARTROLI J, GARCIA-RAFANELL J, FORN J: 4-Substituted 2-alkoxytetrahydro furans as potent and long-lasting PAP antagonists. J. Med. Chem. (1992) 35: 676–683.
   PubMed Web of Science ®Google Scholar
• MERLOS M, GOMEZ LA, GIRAL M, VERICAT ML, GARCIA-RAFANELL J, FORN J: Effects of PAR antagonists in mouse ear oedema induced by several inflammatory agents. Br. J. Pharmacol. (1991) 104: 990–994.
   PubMed Web of Science ®Google Scholar
• TERASHITA Z-I, KAWAMURA M, TAKATANI M, TSUSHIMAS, IMURA Y, NISHIKAWA K: Beneficial effects of TCV-309, a novel potent and selective platelet-activating factor antagonist in endotoxin and anaphylactic shock in rodents. J. Pharmacol. Exp. Ther. (1992) 260: 748–755.
   PubMedGoogle Scholar
• Scrip (1993) 1802: 27.
   Google Scholar
• TERASHITA Z-I, TAKATANI M, NISHIKAWA K: Pharma-cological profile of TCV-309, a potent PAP antagonist I Lipid Mediators (1992) 5: 183–185.
   Google Scholar
• KAWAMURA M, TERASHITA Z-I, IMURA Y, SHINO A, NISHIKAWA K: Inhibitory effect of TCV-309, a novel platelet-activating factor (PAP) antagonist, on endo-toxin-induced disseminated intravascular coagulation in rats: Possible role of PAP in tissue factor generation. Thromb. Res. (1993) 70: 281–293.
   PubMedGoogle Scholar
• KAWAMURA M, KITAYOSHI T, TERASHITA Z-I, FUJIWARA S, TAKATANI M, NISHIKAWA K: Effects of TCV-309, a novel PAP antagonist, on circulatory shock and hema-tological abnormality induced by endotoxin in dogs. J. Lipid Mediators Cell Signalling (1994) 9: 255–265.
   PubMedGoogle Scholar
• KUIPERS B, VAN DER POLL T, LEVI M, VAN DEVENTER SJH, TEN CANTE H, IMAI Y, HACK CE, TEN GATE JW: Platelet-activating factor antagonist TCV-309 attenuates the in-duction of the cytokine network in experimental endotoxemia in chimpanzees. J. Immunol. (1994) 152: 2438–2446.
   PubMed Web of Science ®Google Scholar
• KATOH S, KOIKE A, ABE T, KODAMA I, TOYAMA J: Protective action of a platelet-activating factor (PAP) antagonist, TCV-309, against ischaemia-reperfusion in-jury in langendorff-perfused rabbit hearts. Environ. Med. (1992) 36: 115–118.
   Google Scholar
• KAWAHARA K, TAGAWA T, TAKAHASHI T, AKAMINE S, NAKAMURA A, YAMAMOTO S, MURAOKA S, TOMITA M: The effect of the platelet-activating factor inhibitor TCV-309 on reperfusion injury in a canine model of ischenaic lung. Tranplantation (1993) 55: 1438–1439.
   PubMedGoogle Scholar
• NISHIYAMA R, NAKAMURA S, SUZUKI S, BABA S: Platelet-activating factor in hepatic ischaemia/reperfusion in-jury. Transplantation (1993) 55: 1261–1265.
   PubMedGoogle Scholar
• TOKUTOMI T, SIGEMORI M, KIKUCHI T, HIROHATA M: Effect of platelet-activating factor antagonist on brain injury in rats. Acta Neurochir. (1994) 60 (Suppl.): 508–510.
   Google Scholar
• Scrip (1994) 1927: 22.
   Google Scholar
• HEUER HO: WEB 2347: Pharmacology of a new very potent and long acting hetrazepinoic PAP-antagonist and its action in repeatedly sensitized guinea-pigs. J. Lipid Mediators (1991) 4: 39.
   PubMedGoogle Scholar
• Detailed report on pharmacology of WEB 2347 that contains com-parative data for WEB 2086 and WEB 2170.
   Google Scholar
• SPENCE DPS, JOHNSON SL, CALVERLEY PMA, DHILLON P, HIGGINS C, RAMHANIADANY E, TURNER S, WINNING A, WINTER J. HOLGATE ST: The effect of the orally active platelet-activating factor antagonist WEB 2086 in the treatment of asthma. Am. J. Respir. Crit. Care Med. (1994) 149: 1142–1148.
   Google Scholar
• KUSANO K, TANAKA S, ABE Y, IDA S, YUZURIHA T: Pharmacokinetics of a new thienodiazepine platelet-ac-tivating factor receptor antagonist (E-6123) in labora-tory animals. Is there a metabolic polymorphism in the rhesus monkey? Xenobiotica (1993) 6: 589–598.
   Google Scholar
• TANAKA E, DALING Z, ABE K, NAKAMURA T, HORIE T: Dual effects of a novel thienodiazepine platelet-activat-ing factor antagonist, on drug-oxidizing enzymes in beagle dog. Xenobiotica (1994) 4: 293–300.
   Google Scholar
• KUZANO K, TADANO K, TANAKA S, KAGEI Y, UEDA M, MIYAZAWA S, ABE Y, IDA S, YUZURIHA T: Development of radioimmunoassay for the novel platelet-activating factor receptor antagonist, E-6123, and its application to pharmacokinetics in laboratory animals. Biol. pharm. Bull. (1994) 17(2): 334–339.
   PubMedGoogle Scholar
• DUCHIER J, AURICHE C, GUINOT P: Effect of BN 50730, a specific PAP antagonist, on PAP-Induced platelet aggre-gation and skin responses in healthy human volun-teers. Drug Invest. (1994) 8(2): 95–103.
   Google Scholar
• G1RAULT J, LONGEVIIT.F D, MALGOUYAY, ISTIN B, LE-comTE G, FOURTILLAN JB: Simultaneous quantitative measurement of a new platelet-activating factor antago-nist (BN 50730) and its two main metabolites in human plasma and urine by LC-MS. Chromatographia (1994) 3/4: 228–238.
   Google Scholar
• PIRES ALA, SILVA PMR, PASQUALE C, CASTRO-FARIA-NETO HC, BOZZA PT, CORDEIRO RSB, RAE GA, BRAQUET P, LAGENTE V, MARTINS MA: Long-lasting inhibitory activity of the hetrazepinoic BN 50730 on exudation and cellular alterations evoked by PAP and LPS. Br. J. Phar-macol. (1994) 113: 994–1000.
   PubMedGoogle Scholar
• WALSER A, FLYNN T, MASON C, CROWLEY H, MARESCA C, YAREMKO B, O'DONNELL M: Triazolobenzo- and tria-zolothienodiazepines as potent antagonists of platelet-activating factor. J. Med. Chem. (1991) 34: 1209.
   PubMed Web of Science ®Google Scholar
• Report on the SAR for Ro 24–4736: Comparative data are given for WEB 2086.
   Google Scholar
• CROWLEY HJ, YAREMKO B, SELIG WM, JANERO DR, BUR-GHARDT C, WELTON AF, O'DONNELL M: Pharmacology of a potent platelet-activating factor antagonist Ro 24–4736.1. Pharmacol. Exp. Ther. (1991) 259: 78.
   Google Scholar
• THOMPSON WA, COYLE S, VAN ZEE K, OLDENBURG H, TROUSDALE R, ROGY M, FELSEN D, MOLDAWER L, LOWRY SF: The metabolic effects of platelet-activating factor antagonism in endotoxemic man. Arch. Stag. (1994) 129: 72–79.
   PubMedGoogle Scholar
• SHEPPARD GS, PIREH D, CARRERA GM, SURES MG, HEY-MAN HR, STEINMAN DH, DAVLDSEN SK, PHILLIPS JG, GULNN DE, MAY PD, CONWAY RG, RHEIN DA, CALHOUN WC, ALBERT DH, MAGOG TJ, CARTER GW, SUMMERS JB: 3-(2-(3-Pyridinyl)thia7olidin-4-oyDindoles, a novel se-ries of platelet-activating factor antagonists. J. Med. Chem. (1994) 37: 2011–2032.
   PubMedGoogle Scholar
• Excellent report on the SAR for the Abbott PAF antagonists.
   Google Scholar
• DAVIDSEN SK, SUMMERS JB, ALBERT DH, HOLMS JH, HEYMAN HR, MAGOC TJ, CONWAY RG, RHEIN DA, CAR-TER GW: N-(Acyloxyalkyl)pyridiniura salts as soluble prodrugs of a potent platelet-activating factor antago-nist. J. Med. Chem. (1994) 37(26): 44234429.
   Google Scholar
• Important new approach to the generation of aqueous soluble prodrugs for pyridine based compounds.
   Google Scholar
• TOWNLEY RG, EDA R, HOPP RJ, BEWTRA AK, GILT FN MS: The effect of RP 59227, a platelet-activating factor an-tagonist, against antigen challenge and eosinophil and neutrophll chemotaxis in asthmatics. J. Lipid Mediators Cell Signalling (1994) 10: 345–353.
   PubMedGoogle Scholar
• HERBERT JM, BERNAT A, CLUZEL M, MAFFRAND JP: SR27417, a novel highly potent and long-acting PAP recep-tor antagonist. J. Lipid Mediators Cell Signalling (1994) 10: 149–150.
   Google Scholar
• WYLD P, NIMMO W, HOLLAND T, HERBERT J-M, CLUZEL M: Single rising dose of SR 27417A, a specific PAP receptor antagonist in humans: Tolerability and phar-macological assessment. J. Lipid Mediators Cell Signalling (1994) 10: 155–157.
   Google Scholar
• HERBERT JM, FRALSSE L, BACHY A, VALETTE G, SAW P,LAPLACE M-C, LASSALLE J, ROCHE B, LALE A, KEANE PE, MAFFRAND JP: Biochemical and pharmacological prop-erties of SR 27388, a dual antioxidant and PAP receptor antagonist J. Lipid Mediators Cell Signalling (1993) 8: 31–51.
   PubMedGoogle Scholar
• IMANISHI M, MURAKAMI-URCHIDA H, KOIKE Y, MOROOKA S: Biological effects of the new platelet-acti-vating factor receptor antagonist (+)-cis-3,5-dimethy1-2-(3-pyridy0thiazolidin-4-one-hydrochloride. Arznei mittelforschung/Drug Res. (1994) 44(1): 317–322.
   PubMedGoogle Scholar
• YOKOTA Y, INAMURA N, ASANO M, YAMAMOTO Y, NAKAHARA KUNIO, NOTSU Y, ONO T, 'WATANABE M: Effect of FR128998, a novel PAP receptor antagonist on endotoxin-induced disseminated intravascular coagu-lation. Eur.J. Pharmacol. (1994) 258: 239–246.
   PubMedGoogle Scholar
• KHANNA IK, WELER RM, LENTZ KT, SWENTON L, LANK1NDC: Facile, regioselective synthesis of N-alkylated 2,3-diaminopyridines and imidazo[4,5-b]pyridines. J. Org. Chem. (1995) 60: 960–965.
   Google Scholar
• WHITTAKER M, ASKEW M, BEAUCHAMP CL, BOWIES SA, CACKETT KS, CAMPION C, CHRISTODOULOU M, CHUR-CHILL M, DAVIDSON AIL DAVIS MH, DRUMMOND AH, GALLOWAY WA, GREWAL KS, HIGGS AR, LONGSTAFF DS, MCGUINESS GP, MEIER A, PRATT LM, SAROGLOU L, TIMMIS DJ, WILSON RJ, WOOD LM: Structure-activity relationships for BB-823 and related PAP antagonists. J. Lipid Mediators Cell Signalling (1994) 10: 151–152.
   Google Scholar
• FORMELA LJ, WOOD LM, WHITTAKER M, KINGSNORTH AN: Amelioration of experimental acute pancreatitis with a potent platelet-activating factor antagonist. Br.J. Surg. (1994) 81: 1783–1785.
   PubMed Web of Science ®Google Scholar
• Scrip (1994) 1979: 24.
   Google Scholar
• WHITTAKER M, BEAUCHAMP CL, BOWLES SA, CACKETTK, CHRISTODOULOU M, GALLOWAY WA, LONGSTAFF DS, MCGUINNESS GP, MILLER A, TIMMIS DJ, WOOD LM: BB-823, a PAP receptor antagonist with picomolar activity. Pharmacol. Commun. (1992) 1: 251–257.
   Google Scholar
• PELLON MI, STEIL AA, FURIO V, SANCHEZ CRESPO M: Study of the effector mechanism involved in the pro-duction of haemorrhagic necrosis of the small intestine in rat passive anaphylasris. Br. J. Pharmacol. (1994) 112: 1101–1108.
   PubMedGoogle Scholar
• STEIL AA, RODRIGUEZ MDCG, ALONSO A, SANCIIEZ CRE-SPO M, BOSCA L: Platelet-activating factor: The effector of protein-rich plasma extravasation and nitric oxide synthase induction in rat immune complex peritonitis. Br. J. Pharmacol. (1995) 114: 895–901.
   PubMedGoogle Scholar
• WHITTAKER M, THOMPSON TM, SPAVOLD ZM, PRICE M, MILLER A, GALLOWAY WA, FRAZER F, FLOYD CD, DRUM-MOND AH, DAVIDSON AD, BOWLES SA, BEBBINGTON DS: Cyclic ether acetal platelet-activating factor antagonists 3-Pyridyl derivatives. Bioorg. Med. Chem. Lett. (1993) 3: 1493–1498
   Google Scholar
• WOOD LM, WHITTAKER M, TIMMIS DJ, THOMPSON TM,SAROGLOU L, MILLER A, DAVIDSON AM, CHRISTODOU-LOU MS, CACKETT KS, BOWLES SA, BEBBINGTON DS: Cyclic ether acetal platelet-activating factor antagonists Imiclazo[4,5-c]pyridyl derivatives. Biorg. Med. Chem. Lett. (1993) 3: 1499–1504.
   Google Scholar
• PARRY MJ, ALABASTER VA, CHEESEMAN HE, COOPER K,DESOUZA RN, KEIR RF: Pharmacological profile of UK-74,505, a novel and selective PAP antagonist with potent and prolonged oral activity. J. Lipid Mediators Cell Signal-ling (1994) 10: 251–268.
   PubMedGoogle Scholar
• O'CONNOR BJ, UDEN S, CARTY TJ, ESKRA JD, BARNES PJ, CHUNG KF: Inhibitory effect of UK-74,505, a potent and specific oral platelet-activating factor (PAY) antagonist, on airway and systemic responses to inhaled PAY in humans. Am. J. Respir. Crit. Care Med. (1994) 150: 35–40.
   PubMedGoogle Scholar
• KUITERT LM, KOK PH, UTHAYARKUMAR S, BURKE W, NEWLAND AC, UDEN S, BARNES NC: Effect of the plate-let-activating factor antagonist UK-74,505 on the early and late response to allergan. Am. Rev. Respir. Dis. (1993) 147: 82–86.
   PubMedGoogle Scholar
• HOULIHAN WJ, CHEON SH, PARRINO VA, HANDLEY DA, LARSON DA: Structural modification of 5-ary1-2,3-dihydroimidazo[2,1-a]isoquinoline platelet-activating factor receptor antagonists. J Med. Chem. (1993) 36: 3098–3102.
   PubMedGoogle Scholar
• HOULIHAN WJ, MUNDER PG, HANDLEY DA, CHEON SH, PARRINO VA: Antitumour activity of 5-ary1-2,3-dihy-drohnidazo[2,1-al-isoquinolines. J. Med. Chem. (1995) 38: 234–240.
   PubMed Web of Science ®Google Scholar
• HWANG S-B, LAM M-H, SZALKOWSKI DM, MACINTYRE DE,BACH TJ, LUELL S, MEUER R, SAHOO SP, ALBERTS AW, CHABALA JC: MK 287: A potent specific, and orally active receptor antagonist of platelet-activating factor. J. Lipid Mediators (1993) 7: 115–134.
   PubMedGoogle Scholar
• GIROTRA NN, BIFTU T, PONPIPOM MM, ACTON JJ, AL-BERTS AW, BACH TN, BALL RG, BUGIANESI RL, PARSONS WH, CHABALA JC, DAVIES P, DOEBBER J, DOHERTY J, GRAHAM DW, HWANH S-B, KUO CH, LAM M-H, LUELL S, MACINTYRE DE, MEURER R, ROBERTS CD, SAHOO SP, WV MS: Development, synthesis and biological evaluation of 0-trans-(2S, 5S)-2-[342-oxopropyl)-sulphonyl]-4-n-propoxy-5-(3-hydroxypropoxy)-pheny11-5-(3,4,5,trim ethoxyphenyl)tetrahydrofuran, a potent orally active platelet-activating factor antagonist and its water sol-uble prodrug phosphate ester. J. Med. Chem. (1992) 35: 3474–3482.
   PubMedGoogle Scholar
• HUSSOIN MS, CAI X, SCANNELL RT, YAEGER D, KILLIAN DB, ECKMAN J, HWANG S-B, LIBERTINE-GARAHAN L, QIAN C, YEH CG, IP 5: CMI-206: A potent dual platelet-activating factor antagonist and 5-lipoxygenase inhibi-tor. Bioorg. Med. Chem. Len. (1995) 5: 643–648.
   Google Scholar
• GOLDSTEIN DM, SHEN TV: Dual inhibitors of platelet-ac-tivating factor and 5-lipoxygenase. I 2,4-diary1-1,3-dithiolanes. Med. Chem. Res. (1992) 2: 443–450.
   Google Scholar
• GOLDSTEIN DM, SHEN TV: Dual inhibitors of platelet-activating factor and 5-lipoxygenase. II Novel 2,4-diary1-1,3-dithiolanes with iron chelating functionalities. Med Chem Res (1992) 2: 443–450
   Google Scholar
• PEET NP, BURKEHART JP, BROERSMA RJ, HEMINGER EF: Synthesis of a 2,5-diaryloxazoline as a potential plate-let-activating factor antagonist. J. Het. Chem. (1994)31(2): 419–423.
   Google Scholar
• EUKUSHI H, MABUCHI H, ITOH K, TERASHITA Z-I, NISHIKAWA K, SUGIHARA H: Synthesis and platelet-acti-vating factor antagonist activities of 1,4-disubstituted piperazine derivatives. Chem. Pharm. Bull. (1994) 42(3). 541–550.
   PubMedGoogle Scholar
• FUKUSHI H, MABUCHI H, ITOH K, TERASHITA NISHIKAWA K, SUGIHARA H: Synthesis and platelet-acti-vating factor antagonist activities of trisubstituted piperazine derivatives. Chem. Pharm. Bull. (1994) 42(3): 551–559.
   PubMedGoogle Scholar
• DIVE G, GODFROID JJ, BRASSEUR JJ, BATE JP, HEYMANS F, DUPONT L, BRAQLTET P: Cache-Oreilles effect of se-lected high potency platelet-activating factor antago-nists. J. Lipid Mediators (1989) 1: 102–215.
   Google Scholar
• LAMOURI A, HEYMANS F, TAVET F, DIVE G, BATE J-P, BLAVET N, BRAQUET P, GODFROID JJ: Design and mod-elling of new platelet-activating factor antagonists. L Synthesis and biological activity of 1,4-bis(3,4,5-trimethoxybenzoy1)-24(substituted carbonyl and car-bamoyl)oxylmethyl]piperazines. J Med. Chem. (1993) 36: 990–1000.
   Google Scholar
• HEYMANS F, LAMOURI A, BATE J-P, DIVE G, GODFROID JJ: Design and modelling of new PAF antagonists:1,4-bis-(3,4,5-trimethoxy-benzoy1)-2-substituted carbonyloxy methyl piperazines. J. Lipid Mediators Cell Signalling (1994) 10: 153–154.
   Google Scholar
• KORTH R, NUNEZ D, BIDAULT J, BENVENISTE J: Compari-son of three PAF-acether receptor antagonist gink-golides. Eur. J. Pharmacol. (1988) 152: 101.
   PubMed Web of Science ®Google Scholar
• DHAINAUT J-FA, TENAILLON A, LE TULZO Y, SCHLEMMER B, SOLET J-P, WOLFF J, HOLZAPFEL L, ZENI F, DREYFUSS D, MIRA J-P, DE VATHAIRE F, GUINOT P: BN 52021 Sepsis Study Group: Platelet-activating factor receptor antago-nist BN52021 in the treatment of severe sepsis: A ran-domised, doubleblind, placebo-controlled, multicentre clinical triaL Crit. Care Med. (1994) 22: 1720–1728.
   Google Scholar
• GRINO JM: BN 52021 study group in renal transplanta-tion: BN 52021: A platelet activating factor antagonist for preventing post-transplant renal failure. A double blind, randomised study. Ann. Intern. Med. (1994) 121: 345–347.
   Google Scholar
• NATHAN N, MERCURY P, DENIZOT Y, CORNU E, LASKAR M, ARNOUX B, FEISS P: Effects of the platelet-activating factor receptor antagonist BN 52021 on hematologic variables and blood loss during and after cardiopul-monary bypass. Anesth. Analg. (1994) 79: 205–211.
   PubMedGoogle Scholar
• CHU M, PATEL MG, GULLO VP, TRUUMEES I, PUAR MS: Sch 47918: A novel PAY antagonist from the fungus Photna sp. J. Org. Chem. (1992) 57: 5817–5818.
   Web of Science ®Google Scholar
• SUGANO M, SATO A, IIJIMA Y, FURUYA K, HARUYAMA H, YODA K, HATA T: Phomactins, novel PAY antagonists from marine fungus Phoma sp. J. Org. Chem. (1994) 59: 564–569.
   Google Scholar
• DEMONCHAUX P, LENOIR P, AUGERT G, DUPASSIEUX P: Design of pyrrolo-1,4-benzoxazine derivatives as In-hibitors of 5-lipoxygenase and PAP antagonists with antihistaminic properties. Bioorg. Med. Chem. Lett (1994) 4(20): 2383–2388.
   Google Scholar
• PARIS D, COTTIN M, DEMONCHAUX P, AUGERT G, DU-PASSIEUX P, LENOIR P, PECK MJJASSERAND D: Synthesis, structure-activity relationships, and pharmacological evaluation of pyrrolo[3,2,1-ij]quinoline derivatives: Po-tent histamine and platelet-activating factor antago-nism and 5-lipoxygenase inhibitory properties. Potential therapeutic application in asthma. J. Med. Chem. (1995) 38: 669–685.
   Google Scholar
• BILLAH MM, CHAPMAN RW, EGAN RW, GILCHREST H, PIWINSKI JJ, SHERWOOD J, SIEGEL MI, WEST JR RE, ICREUTNER W: Sch 37370: A potent, orally active, dual antagonist of platelet-activating factor and histamine./ Pharmacol. Exp. Ther. (1990) 255: 1090–1096.
   PubMedGoogle Scholar
• BILLAH MM, CHAPMAN RW, WATNICK AS, EGAN RW, SIEGEL MI, KREUTNER W: Sch 37370: A new drug com-bining antagonism of platelet-activating factor (PAP) with antagonism of histamine. Agents Actions Suppl. (1991) 34: 313–321.
   PubMedGoogle Scholar
• WONG JIC, PIWINSKI JJ, GREEN MJ, GANGULY AK, ANTHES JC, BILLAH MM: Dual antagonists of platelet-activating factor and histamine. 2. Pyridine ring substitution of N-acety1-4-(8-chloro-5,6-dihydro-11H-benzo[5,6)cyclo-hepta11,2-b]pyridin-11-ylidene) piperidines. Bioorg. Med. Chem. Lett. (1993) 3: 1073–1078.
   Google Scholar
• CARCELLER E, MERLOS M, GIRAL M, BALSA D, ALAMANSA C, BARTROLI J, GARCIA-RAFANELL J, FORN J: [(3-Pyridy-lalkyl)-piperidylidenelbenzocyclo-heptapyridine de-rivatives as dual antagonists of PAP and histamine. J. Med. Chem. (1994) 37: 2697–2703.
   PubMed Web of Science ®Google Scholar
• HODGKIN EE, MILLER A, WHITTAKER M: A partial phar-macophore for the platelet-activating factor (PAP) re-ceptor. Bioorg. Med. Chem. Lea. (1992) 2: 597–602.
   Google Scholar
• HODGKIN EE, MILLER A, \WHITTAKER M: A Monte Carlo pharmacophore generation procedure: Application to the human PAP receptor. J. Comput-Aid. Mol. Des. (1993) 7: 515–534.
   PubMedGoogle Scholar
• BATT JP, LAMOURI A, TAVET F, HEYMANS F, DIVE G, GODFROID J-J: New hypothesis on the conformation of the PAP-receptor from studies on the geometry of selected platelet-activating factor-antagonists. J. Lipid Mediators (1991) 4: 343–346.
   PubMedGoogle Scholar
• SCHAMBYE HT, HJORTH SA, BERGSMA DJ, SATHE GJ, SCHWARTZ TW: Differentiation between binding sites for angiotensin Ii and nonpeptide antagonists on the angiotensin II type 1 receptors. Proc. Natl. Acad. Sci. USA (1994) 91: 7046–7050.
   PubMed Web of Science ®Google Scholar
• LEE JA, BRINKMANN JA, LONGTON ED, PEISHOFF CE, LAGO MA, LEBER JD, COUSINS RD, GAO A, STADEL JM, KUMAR CS, OHLSTEIN EH, GLEASON JG, ELLIOTT JD: Lysine 182 of endothelin B receptor modulates agonist selectivity and antagonist affinity: Evidence for the overlap of peptide and non-peptide ligand binding sites. Biochemistry (1994) 33: 14543–14549.
   PubMedGoogle Scholar
• LE SOLLEU H, DUBOST J-P, LANGLOIS M-H, Kt:TMMER E: PAP antagonists' pharmacophore determination - use of combined molecular electrostatic potential and mo-lecular lipophilicity potential. Bull. Soc. Marin. Bordeaux (1993) 132: 7–28.
   Google Scholar
• LE SOLLEU H, LANGLOIS M-II, KUMMER E, DUBOST J-P: Determination of a PAP antagonist pharmacophore using combined molecular electrostatic potential and molecular lipophilicity potential. Drug Des. Discov. (1994) 12: 149–167.
   PubMedGoogle Scholar
• KAITHARA A, KOMOOKA H, KAMIYA K, YONEDA T, YONEDA S, NAKAMLTRA M, SHIMIZU T, UMEYAMA H: Three-dimensional model of the human PAP receptor. J. Lipid Mediators Cell Signalling (1994) 9: 185–196.
   PubMedGoogle Scholar